Annual EBIT
-$43.64 M
-$14.38 M-49.15%
December 31, 2024
Summary
- As of March 10, 2025, VYNE annual earnings before interest & taxes is -$43.64 million, with the most recent change of -$14.38 million (-49.15%) on December 31, 2024.
- During the last 3 years, VYNE annual EBIT has fallen by -$4.59 million (-11.76%).
- VYNE annual EBIT is now -846.98% below its all-time high of -$4.61 million, reached on December 31, 2015.
Performance
VYNE EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
-$12.77 M
+$321.00 K+2.45%
December 1, 2024
Summary
- As of March 10, 2025, VYNE quarterly earnings before interest & taxes is -$12.77 million, with the most recent change of +$321.00 thousand (+2.45%) on December 1, 2024.
- Over the past year, VYNE quarterly EBIT has stayed the same.
- VYNE quarterly EBIT is now -159.29% below its all-time high of -$4.92 million, reached on December 31, 2016.
Performance
VYNE Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
-$43.64 M
-$5.94 M-15.75%
December 1, 2024
Summary
- As of March 10, 2025, VYNE TTM earnings before interest & taxes is -$43.64 million, with the most recent change of -$5.94 million (-15.75%) on December 1, 2024.
- Over the past year, VYNE TTM EBIT has stayed the same.
- VYNE TTM EBIT is now -786.03% below its all-time high of -$4.92 million, reached on December 31, 2016.
Performance
VYNE TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
VYNE EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -49.1% | 0.0% | 0.0% |
| 3 y3 years | -11.8% | 0.0% | 0.0% |
| 5 y5 years | +42.8% | 0.0% | 0.0% |
VYNE EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -49.1% | at low | -117.4% | +2.5% | -49.1% | at low |
| 5 y | 5-year | -49.1% | +82.6% | -117.4% | +92.3% | -49.1% | +82.6% |
| alltime | all time | -847.0% | +82.6% | -159.3% | +92.3% | -786.0% | +82.6% |
VYNE Therapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | -$43.64 M(+49.1%) | - | - |
| Dec 2024 | - | -$12.77 M(-2.5%) | -$43.64 M(+15.8%) |
| Sep 2024 | - | -$13.09 M(+25.9%) | -$37.70 M(+22.2%) |
| Jun 2024 | - | -$10.40 M(+40.9%) | -$30.84 M(+0.3%) |
| Mar 2024 | - | -$7.38 M(+8.0%) | -$30.76 M(+5.1%) |
| Dec 2023 | -$29.26 M(-14.7%) | -$6.83 M(+9.6%) | -$29.26 M(-3.8%) |
| Sep 2023 | - | -$6.23 M(-39.6%) | -$30.41 M(-9.2%) |
| Jun 2023 | - | -$10.32 M(+75.6%) | -$33.51 M(+6.5%) |
| Mar 2023 | - | -$5.88 M(-26.4%) | -$31.48 M(-8.2%) |
| Dec 2022 | -$34.30 M(-12.2%) | -$7.98 M(-14.5%) | -$34.30 M(-2.4%) |
| Sep 2022 | - | -$9.33 M(+12.6%) | -$35.13 M(-4.0%) |
| Jun 2022 | - | -$8.29 M(-4.6%) | -$36.60 M(-3.5%) |
| Mar 2022 | - | -$8.69 M(-1.5%) | -$37.92 M(-2.9%) |
| Dec 2021 | -$39.05 M(-84.5%) | -$8.82 M(-18.3%) | -$39.05 M(-25.3%) |
| Sep 2021 | - | -$10.80 M(+12.4%) | -$52.25 M(-19.7%) |
| Jun 2021 | - | -$9.61 M(-2.1%) | -$65.07 M(-70.7%) |
| Mar 2021 | - | -$9.81 M(-55.4%) | -$222.08 M(-11.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2020 | -$251.44 M(+229.8%) | -$22.02 M(-6.8%) | -$251.44 M(+0.0%) |
| Sep 2020 | - | -$23.62 M(-85.8%) | -$251.35 M(+2.5%) |
| Jun 2020 | - | -$166.63 M(+325.4%) | -$245.15 M(+156.1%) |
| Mar 2020 | - | -$39.17 M(+78.6%) | -$95.74 M(+25.6%) |
| Dec 2019 | -$76.24 M(+39.8%) | -$21.93 M(+25.8%) | -$76.24 M(+4.8%) |
| Sep 2019 | - | -$17.43 M(+1.2%) | -$72.75 M(+5.4%) |
| Jun 2019 | - | -$17.22 M(-12.5%) | -$69.03 M(+13.2%) |
| Mar 2019 | - | -$19.67 M(+6.7%) | -$60.98 M(+11.8%) |
| Dec 2018 | -$54.53 M(+84.3%) | -$18.44 M(+34.6%) | -$54.53 M(+19.7%) |
| Sep 2018 | - | -$13.70 M(+49.4%) | -$45.57 M(+13.3%) |
| Jun 2018 | - | -$9.17 M(-30.6%) | -$40.20 M(+7.9%) |
| Mar 2018 | - | -$13.22 M(+39.5%) | -$37.26 M(+25.9%) |
| Dec 2017 | -$29.59 M(+106.5%) | -$9.48 M(+13.7%) | -$29.59 M(+18.2%) |
| Sep 2017 | - | -$8.34 M(+33.9%) | -$25.04 M(+49.9%) |
| Jun 2017 | - | -$6.22 M(+12.1%) | -$16.70 M(+59.4%) |
| Mar 2017 | - | -$5.55 M(+12.8%) | -$10.48 M(+112.8%) |
| Dec 2016 | -$14.33 M(+211.0%) | -$4.92 M | -$4.92 M |
| Dec 2015 | -$4.61 M | - | - |
FAQ
- What is VYNE Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for VYNE Therapeutics?
- What is VYNE Therapeutics annual EBIT year-on-year change?
- What is VYNE Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for VYNE Therapeutics?
- What is VYNE Therapeutics quarterly EBIT year-on-year change?
- What is VYNE Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for VYNE Therapeutics?
- What is VYNE Therapeutics TTM EBIT year-on-year change?
What is VYNE Therapeutics annual earnings before interest & taxes?
The current annual EBIT of VYNE is -$43.64 M
What is the all time high annual EBIT for VYNE Therapeutics?
VYNE Therapeutics all-time high annual earnings before interest & taxes is -$4.61 M
What is VYNE Therapeutics annual EBIT year-on-year change?
Over the past year, VYNE annual earnings before interest & taxes has changed by -$14.38 M (-49.15%)
What is VYNE Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of VYNE is -$12.77 M
What is the all time high quarterly EBIT for VYNE Therapeutics?
VYNE Therapeutics all-time high quarterly earnings before interest & taxes is -$4.92 M
What is VYNE Therapeutics quarterly EBIT year-on-year change?
Over the past year, VYNE quarterly earnings before interest & taxes has changed by $0.00 (0.00%)
What is VYNE Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of VYNE is -$43.64 M
What is the all time high TTM EBIT for VYNE Therapeutics?
VYNE Therapeutics all-time high TTM earnings before interest & taxes is -$4.92 M
What is VYNE Therapeutics TTM EBIT year-on-year change?
Over the past year, VYNE TTM earnings before interest & taxes has changed by $0.00 (0.00%)